Researchers sought to determine the effects and cerebrospinal fluid concentrations of treatment with bictegravir, emtricitabine, and tenofovir in patients with HIV-related central nervous system impairment.
Tuberculosis preventive treatment completion is higher with three months of rifapentine-isoniazid than six months of isoniazid among patients with HIV receiving antiretroviral therapy.
Investigators performed a genome-wide screening study to determine whether silencing specific genes induces apoptosis of HIV-infected macrophages.
For men who have sex with men and transgender women, long-acting injectable cabotegravir, is superior to TDF-FTC for preventing HIV infection.
Lenacapavir is an investigational, long-acting HIV-1 capsid inhibitor designed to inhibit HIV replication at multiple stages of its lifecycle.
Study researchers sought to differentiate between HIV-associated neurocognitive disorder and true Alzheimer disease in patients with HIV.
HIV incidence remains low over three years of follow-up among individuals at high risk of HIV receiving preexposure prophylaxis (PrEP).
Structural concerns, racial and socioeconomic issues, and state- and federal-level policy present challenges when trying to address the intersecting epidemics of opioid use disorder and HIV.
Recently, the annual incidence of HIV infections has been on the decline, reaching 34,800 infections in 2019.
IMPAACT and VESTED assessed pregnancy outcomes and viral suppression status for pregnant women with HIV undergoing treatment with antiretroviral agents.
